Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Q3 2018 Earnings Presentation

20 slides from Paratek Pharmaceuticals's earnings presentation, Nov 6, 2018

  1. Slide 1: Third Quarter 2018 Financial Results and Business Update

    Third Quarter 2018 Financial Results and Business Update November 6, 2018 Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories. Exhibit 99.1

  2. Slide 2: Q3 2018 Earnings Call Agenda

    Q3 2018 Earnings Call Agenda Introduction Ben Strain, Executive Director, Investor Relations & Corporate Communications Third Quarter Overview and Business Update Michael F. Bigham, Chief Executive Officer and Chairman of the Board Commercial Update Adam Woodrow, Chief Commercial Officer Financial U

  3. Slide 3: Forward-looking statements disclaimer

    Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The info

  4. Slide 4: Third Quarter 2018 Overview & Business Update

    Third Quarter 2018 Overview & Business Update Michael F. Bigham, Chief Executive Officer & Chairman of the Board Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  5. Slide 5: Third Quarter Updates

    Third Quarter Updates Achieved a number of significant milestones NUZYRATM approved in the U.S. First once-daily IV and oral antibiotic to be FDA approved to treat both CABP and ABSSSI in nearly 20 years Commercial preparations continue to advance with anticipated February 2019 launch of NUZYRA SEYS

  6. Slide 6: Paratek Pipeline

    Paratek Pipeline Compelling Life-cycle Opportunities Research Preclinical Phase 1 Phase 2 Phase 3 Pre-Registration NDA Filing NDA Approved Commercial Rights SEYSARATM (sarecycline) (U.S.) (ex-U.S.) (Global*) uUTI (IV & Oral) – QIDP ABSSSI (IV & Oral) – QIDP + SPA CABP (IV & Oral) – QIDP + SPA Inflam

  7. Slide 7: Strong Track Record Delivering on Milestones

    Strong Track Record Delivering on Milestones Omadacycline Events Timing Results ABSSSI Phase 3 data: IV and oral Q2 2016 Positive Phase 3 data UTI Phase 1b data: PK/PD Q4 2016 Proof-of-principle CABP Phase 3 data: IV and oral Q2 2017 Positive Phase 3 data ABSSSI Phase 3 data: Oral-only Q3 2017 Posit

  8. Slide 8: Strengthened the Balance Sheet

    Strengthened the Balance Sheet Earned a $12 million milestone from Almirall, LLC upon FDA approval of SEYSARA, which will be reflected in the fourth quarter 2018 financial statements The FDA approval of NUZYRA extended the interest-only period and maturity date for Hercules term loan Earned a $5 mil

  9. Slide 9: Commercial Update

    Commercial Update Adam Woodrow, Chief Commercial Officer Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  10. Slide 10: There are Unmet Needs that NUZYRA Will Address

    More Oral Options New Therapies to Overcome Drug Resistance Greater Safety Alternative to Quinolones There are Unmet Needs that NUZYRA Will Address Reduce Hospital Length of Stay Reduce Nursing Time Lack of Different Class Options Reduce Usage of Multi-Drug Combinations NUZYRA Attributes Provide A M

  11. Slide 11: Success Begins in the Hospital with Specialists

    Success Begins in the Hospital with Specialists “Go-Home” Strategy to Minimize Hospital Stay IDs ER HCPs Hospitalists Pulmonologists PharmD IDs Allied HCPs Launch and Beyond HOSPITAL Internal Medicine Primary Care Provider NPs, PAs Urgent Care Year 2 and Beyond COMMUNITY

  12. Slide 12: Focused Launch Targeting Early Adopters

    Focused Launch Targeting Early Adopters Expansion to ~80 Representatives by Year End 2019 Physician Segments Guideline and protocol driven Wait for Early Adopters to trial and use Convenient features with IV to oral transition Focused on broad spectrum and efficacy Launch in February 2019 with 40 Sa

  13. Slide 13: Field Force Has Two Simultaneous Objectives

    Influencers: IDs PharmD IDs Pharmacy Directors Microbiologists = Field Force Has Two Simultaneous Objectives Institutional Access + Demand Generation Adoption Formulary/Protocols Specialty Access & Buying + Institutional Access Prescribers: IDs ER Hospitalists Pulmonologists Trial & Usage Demand Gen

  14. Slide 14: NUZYRA Priced for Value

    NUZYRA Priced for Value NUYZYRA will have a WAC price of $345 per vial for IV and WAC price of $197.50 per tablet for oral formulation The maintenance dose for the oral formulation is two tablets once per day Announcement of price allows for some formulary committees, in particular government payers

  15. Slide 15: History Can Repeat Itself

    History Can Repeat Itself… Today: Slower starts…But with the Right Attributes, a Strong Finish Recent AB Launches: antibiotics launched since 2010 that have at least 36 months of data - Avycaz, Dalvance, Orbactiv, Sivextro, Teflaro, & Zerbaxa (does not include Dificid or new formulations/line extens

  16. Slide 16: Financial Update

    Financial Update Douglas W. Pagán, Chief Financial Officer Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  17. Slide 17: Condensed Consolidated Statements of Operations

    Condensed Consolidated Statements of Operations (unaudited) (in thousands, except loss per share data)

  18. Slide 18: Strong Balance Sheet

    Strong Balance Sheet Key Metrics (unaudited) 9/30/18 balance Total Cash, Cash Equivalents, and Marketable Securities $310.9 million Long-term Debt Obligation $228.7 million Basic Shares Outstanding 31,781,488 Total Potentially Dilutive Securities* 17,162,073 Funding Projected through Q1 2021 * Inclu

  19. Slide 19: Closing Remarks

    Closing Remarks Michael F. Bigham, Chief Executive Officer & Chairman of the Board Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

  20. Slide 20: Well-Positioned for Future Growth

    Well-Positioned for Future Growth Focused on Execution + New Value Creation Near-term Focus New Sources of Value Launch of NUZYRA Prudent Operating Expense Management Non-Dilutive Sources of Capital Life-cycle Opportunities for NUZYRA Bio-Defense Product / Pipeline Expansion

Paratek Pharmaceuticals — Q3 2018 Earnings Presentation on 6ix